Literature DB >> 2647155

Positive effects of captopril in the behavioral despair swim test.

W J Giardina1, D M Ebert.   

Abstract

Captopril, an angiotensin II converting enzyme (ACE) inhibitor, was evaluated for potential antidepressive activity on the forced swim-induced behavioral despair (immobility) test in mice. Captopril (10.0 and 30.0, mg/kg ip) significantly reduced immobility and mimicked the effects of the antidepressants imipramine (30.0 mg/kg, ip) and mianserin (3.0, 10.0, and 30.0 mg/kg, ip). Captopril increased the motor activity of mice at these same dosages. Naloxone (2.0 mg/kg, ip) blocked the effects of captopril (30.0 mg/kg, ip) in the swim test. These data suggest that captopril has potential antidepressive activity. However, the conclusion is guarded, as the positive effects may be related to motor stimulation. The blockade of the captopril effects by naloxone suggests that brain opioid peptides play a role in this behavioral effect of captopril.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2647155     DOI: 10.1016/0006-3223(89)90240-0

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  10 in total

Review 1.  On the physiology of metazoa.

Authors:  A R Ameen
Journal:  Experientia       Date:  1996-03-15

2.  Mineralocorticoid receptor antagonism prevents hedonic deficits induced by a chronic sodium appetite.

Authors:  Michael J Morris; Elisa S Na; Alan Kim Johnson
Journal:  Behav Neurosci       Date:  2010-04       Impact factor: 1.912

3.  AGTR1 gene variation: association with depression and frontotemporal morphology.

Authors:  Warren D Taylor; Sophiya Benjamin; Douglas R McQuoid; Martha E Payne; Ranga R Krishnan; James R MacFall; Allison Ashley-Koch
Journal:  Psychiatry Res       Date:  2012-06-15       Impact factor: 3.222

Review 4.  The Potential Therapeutic Capacity of Inhibiting the Brain Renin-Angiotensin System in the Treatment of Co-Morbid Conditions in Epilepsy.

Authors:  Natasha Ivanova; Jana Tchekalarova
Journal:  CNS Drugs       Date:  2019-11       Impact factor: 5.749

5.  Facilitation of TRKB Activation by the Angiotensin II Receptor Type-2 (AT2R) Agonist C21.

Authors:  Liina Laukkanen; Cassiano R A F Diniz; Sebastien Foulquier; Jos Prickaerts; Eero Castrén; Plinio C Casarotto
Journal:  Pharmaceuticals (Basel)       Date:  2021-08-06

Review 6.  Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets.

Authors:  John W Wright; Brent J Yamamoto; Joseph W Harding
Journal:  Prog Neurobiol       Date:  2007-11-19       Impact factor: 11.685

Review 7.  Vascular growth factors in neuropsychiatry.

Authors:  Samuel S Newton; Neil M Fournier; Ronald S Duman
Journal:  Cell Mol Life Sci       Date:  2013-03-12       Impact factor: 9.261

8.  Elastase-2 Knockout Mice Display Anxiogenic- and Antidepressant-Like Phenotype: Putative Role for BDNF Metabolism in Prefrontal Cortex.

Authors:  C R A F Diniz; C Becari; A Lesnikova; C Biojone; M C O Salgado; H C Salgado; L B M Resstel; F S Guimarães; E Castrén; P C Casarotto; S R L Joca
Journal:  Mol Neurobiol       Date:  2018-01-30       Impact factor: 5.590

9.  Effects of Aqueous Extract of Lycopersicum esculentum L. var. "Camone" Tomato on Blood Pressure, Behavior and Brain Susceptibility to Oxidative Stress in Spontaneously Hypertensive Rats.

Authors:  Maria Frosini; Paola Marcolongo; Alessandra Gamberucci; Gabriella Tamasi; Alessio Pardini; Roberta Giunti; Paolo Fiorenzani; Anna Maria Aloisi; Claudio Rossi; Federica Pessina
Journal:  Pathophysiology       Date:  2021-03-18

Review 10.  The renin-angiotensin system: a possible new target for depression.

Authors:  João Vian; Círia Pereira; Victor Chavarria; Cristiano Köhler; Brendon Stubbs; João Quevedo; Sung-Wan Kim; André F Carvalho; Michael Berk; Brisa S Fernandes
Journal:  BMC Med       Date:  2017-08-01       Impact factor: 8.775

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.